Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomised, Double-blind, Placebo Controlled Phase II, Dose-ranging Study of the Safety, Tolerability and Immunogenicity of Live Attenuated ChimeriVax™-JE Vaccine (Lyophilised)

NCT00981630 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00981630
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00981630 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomised, Double-blind, Placebo Controlled Phase II, Dose-ranging Study of the Safety, Tolerability and Immunogenicity of Live Attenuated ChimeriVax™-JE Vaccine (Lyophilised)
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2004
Completion date
November 30, 2007
Enrollment
128 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

japanese encephalitis